GH Research PLC (GHRS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GHRS SEC filings page.
This page shows GH Research PLC (GHRS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
GH Research PLC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
GH Research PLC passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
GH Research PLC reported a net loss of $48.3M while operations used $43.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
GH Research PLC recorded an outflow of $12.3M in free cash flow in Q4 2025, representing a cash shortfall after capex. This represents a decrease of 17.9% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.
GH Research PLC held $246.3M in cash against $147K in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
GH Research PLC invested $19K in capex in Q4 2025, funding long-term assets and infrastructure. This represents a decrease of 24.0% from the same quarter a year earlier. Against the prior quarter it is down 51.3%.
Not reported for Q4 2025.
Not reported for Q4 2025.
GHRS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
GHRS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'2510-Q | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $288.2M+53.1% | $302.0M+51.3% | $313.4M+51.4% | $320.5M+47.3% | $188.3M-16.8% | $199.6M-14.2% | $207.0M-13.9% | $217.6M |
| Current Assets | $286.0M+85.4% | $294.8M+90.3% | $293.9M+92.2% | $294.7M+83.6% | $154.2M-6.0% | $154.9M-5.5% | $152.9M-8.1% | $160.5M |
| Cash & Equivalents | $246.3M+144.3% | $249.7M+177.2% | $253.9M+191.4% | $245.0M+216.1% | $100.8M+28.5% | $90.1M+4.2% | $87.1M-10.1% | $77.5M-26.3% |
| Total Liabilities | $8.5M-8.5% | $10.6M+3.7% | $10.2M+23.5% | $10.2M+30.7% | $9.3M+27.1% | $10.2M+50.8% | $8.3M+13.9% | $7.8M |
| Current Liabilities | $8.4M-6.4% | $10.4M+6.3% | $10.0M+27.7% | $9.9M+36.3% | $9.0M+33.6% | $9.8M+59.6% | $7.8M+19.0% | $7.3M |
| Non-Current Liabilities | $147K-60.2% | $217K-52.6% | $283K-43.1% | $322K-42.6% | $369K-41.5% | $458K-30.7% | $497K-32.1% | $561K |
| Long-Term Debt | $147K-60.2% | $217K-52.6% | $283K-43.1% | $322K-42.6% | $369K-41.5% | $458K-30.7% | $497K-32.1% | $561K |
| Total Equity | $279.7M+56.3% | $291.4M+53.9% | $303.2M+52.6% | $310.2M+47.9% | $179.0M-18.3% | $189.4M-16.1% | $198.7M-14.7% | $209.7M-13.3% |
| Retained Earnings | -$154.4M-45.1% | -$140.3M-43.7% | -$126.3M-47.6% | -$117.0M-55.0% | -$106.4M-56.7% | -$97.6M-72.3% | -$85.6M-67.2% | -$75.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill.
GHRS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'2510-Q | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.3M-18.0% | -$13.7M-11.2% | -$9.0M+9.8% | -$8.6M+10.7% | -$10.4M-29.2% | -$12.3M-19.0% | -$9.9M-23.8% | -$9.6M-39.4% |
| Depreciation & Amortization | $88K+12.8% | $89K+12.7% | $82K+5.1% | $76K-5.0% | $78K0.0% | $79K-1.3% | $78K-2.5% | $80K+3.9% |
| Capital Expenditures | $19K-24.0% | $39K+875.0% | $59K+637.5% | $4K-66.7% | $25K+4.2% | $4K-50.0% | $8K-82.6% | $12K-45.5% |
| Free Cash Flow | -$12.3M-17.9% | -$13.7M-11.5% | -$9.0M+9.2% | -$8.6M+10.7% | -$10.5M-29.1% | -$12.3M-19.0% | -$9.9M-23.2% | -$9.6M-39.1% |
| Investing Cash Flow | $8.8M-58.6% | $9.8M-36.0% | $15.7M-20.4% | $11.8M+34.7% | $21.3M+88979.2% | $15.3M+191150.0% | $19.7M+42995.7% | $8.8M+116.3% |
| Financing Cash Flow | -$68K-15.3% | -$66K-10.0% | -$1.1M-841.2% | $140.9M+198491.5% | -$59K | -$60K | -$114K | -$71K |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
GHRS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'2510-Q | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -4.8%+1.6pp | -3.1%+2.2pp | -3.5%+0.2pp | N/A | -6.4%-3.9pp | -5.2%-1.9pp | -3.6%+0.9pp |
| Return on Assets | N/A | -4.6%+1.4pp | -3.0%+2.0pp | -3.4%+0.2pp | N/A | -6.1%-3.6pp | -5.0%-1.8pp | -3.5% |
| Current Ratio | 34.13+16.9x | 28.32+12.5x | 29.49+9.9x | 29.71+7.7x | 17.23-7.3x | 15.83-10.9x | 19.60-5.8x | 22.06 |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GH Research PLC GHRS | FY2025 | N/A | -$48.3M | N/A | $1.4B | — |
| Mind Medicine (MindMed) Inc. MNMD | FY2025 | N/A | -$183.8M | N/A | $1.5B | — |
| KalVista Pharmaceuticals, Inc. KALV | FY2025 | N/A | -$183.4M | N/A | $1.4B | — |
| Gyre Therapeutics, Inc. GYRE | FY2025 | $116.6M | $9.9M | 8.5% | $746.5M | 39/100 |
| Zenas BioPharma, Inc. ZBIO | FY2025 | $10.0M | -$377.7M | N/A | $1.8B | 36/100 |
| Praxis Precision Medicines, Inc. PRAX | FY2025 | $0 | -$303.0M | N/A | $7.3B | — |
Where GH Research PLC Ranks
Frequently Asked Questions
Is GH Research PLC profitable?
No, GH Research PLC (GHRS) reported a net income of -$48.3M in fiscal year 2025.
How much debt does GH Research PLC have?
As of fiscal year 2025, GH Research PLC (GHRS) had $246.3M in cash and equivalents against $147K in long-term debt.
What is GH Research PLC's return on equity (ROE)?
GH Research PLC (GHRS) has a return on equity of -17.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GH Research PLC's free cash flow?
GH Research PLC (GHRS) recorded an outflow of $43.7M in free cash flow during fiscal year 2025. This represents a -3.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GH Research PLC's operating cash flow?
GH Research PLC (GHRS) recorded an outflow of $43.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are GH Research PLC's total assets?
GH Research PLC (GHRS) had $288.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are GH Research PLC's capital expenditures?
GH Research PLC (GHRS) invested $121K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is GH Research PLC's current ratio?
GH Research PLC (GHRS) had a current ratio of 34.13 as of fiscal year 2025, which is generally considered healthy.
What is GH Research PLC's debt-to-equity ratio?
GH Research PLC (GHRS) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is GH Research PLC's return on assets (ROA)?
GH Research PLC (GHRS) had a return on assets of -16.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GH Research PLC's P/E ratio?
GH Research PLC (GHRS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.4B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GH Research PLC's price-to-sales ratio?
GH Research PLC (GHRS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.4B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GH Research PLC's Piotroski F-Score?
GH Research PLC (GHRS) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GH Research PLC's earnings high quality?
GH Research PLC (GHRS) reported a net loss of $48.3M while operations used $43.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.